STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Completed · Phase 1

Conditions studied: AML, CML, MDS, Myeloproliferative Disorders

In brief

The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.

Key facts

Study ID

NCT00858572

Run by

Synta Pharmaceuticals Corp.

People needed

31

Starts

2009-03-01

Expected to finish

2013-02-01

Last updated by the study team

2014-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females 18 years or older
• Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol
• Must have acceptable organ function during screening as defined in the protocol

You may not qualify if…

• Pregnant or breast-feeding women
• Patients must meet the washout periods for prior chemotherapies and radiation
• History of stroke within 6 months of treatment
• Poor venous access for study drug administration
• Treatment with chronic immunosuppressants
• Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation

Where it is running

• Study site — Boston, Massachusetts, United States
• Study site — New York, New York, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.